Healthcare - Biotechnology - NASDAQ - US
$ 8.18
-4.77 %
$ 2.49 B
Market Cap
-5.53
P/E
CASH FLOW STATEMENT
-362 M
OPERATING CASH FLOW
-155 M
INVESTING CASH FLOW
463 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Iovance Biotherapeutics, Inc.
| Net Income | -444 M |
| Depreciation & Amortization | 33.1 M |
| Capital Expenditures | -22.3 M |
| Stock-Based Compensation | 62.6 M |
| Change in Working Capital | -6.52 M |
| Others | -4.62 M |
| Free Cash Flow | -384 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||
| Net Income | (444.0) | (395.9) | (342.3) | (259.6) | (197.6) | (123.6) | (92.1) | (52.9) | (27.7) | (12.0) | (25.4) | (3.3) | (25.7) | (1.6) | 15.8 K | 57.1 K |
| Depreciation & Amortization | 33.1 | 21.1 | 14.0 | 1.1 | 1.2 | 1.0 | 1.0 | 1.0 | 1.0 | 88.2 K | 7.09 K | 6.21 K | 2.7 K | 58.6 K | 1.33 K | 1.33 K |
| Deferred Income Tax | (3.5) | 0 | 0 | 1.9 | (3.4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 62.6 | 84.0 | 69.8 | 40.9 | 24.3 | 20.0 | 12.0 | 18.9 | 8.5 | 3.8 | 19.7 | 3.3 | 0 | 0 | 0 | 0 |
| Other Operating Activities | (3.5) | 0.9 | 6.0 | 7.6 | 6.6 | (1.3) | 19 K | 74 K | 8.5 | 3.8 | 22.0 | (3.4) | 19.1 | 0.9 | 0 | 0 |
| Change in Working Capital | (6.5) | (2.9) | 24.6 | 3.0 | 10.0 | 2.7 | 0.4 | 0.4 | (0.2) | (0.5) | (0.3) | 4.5 | 0.4 | 22 K | 8 | 1.5 K |
| Cash From Operations | (361.8) | (292.8) | (227.9) | (205.1) | (158.9) | (101.2) | (78.7) | (32.7) | (18.4) | (8.6) | (3.7) | (2.2) | (6.2) | (0.6) | 14.4 K | 57.3 K |
| INVESTING CASH FLOW | ||||||||||||||||
| Capital Expenditures | (22.3) | (20.4) | (37.6) | (46.8) | (6.9) | (1.2) | (1.0) | (1.5) | (1.1) | (1.6) | 12.7 K | 0 | 31.1 K | 0 | 0 | 0 |
| Other Items | (133.0) | 276.9 | 37.7 | (271.1) | 96.9 | (385.1) | 59.7 | 10.4 | (90.0) | 0 | 0 | 0 | 50 K | 0 | 0 | 0 |
| Cash From Investing Activities | (155.2) | 256.5 | 0.1 | (317.9) | 90.0 | (386.3) | 58.7 | 8.9 | (91.2) | (1.6) | 12.7 K | 0 | 81.1 K | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (0.3) | 0 | (1.3) | (0.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 1.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | 1.5 | 4.6 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (49.5) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.2 | 0.6 | 35.1 | 9.4 | 6.1 | 25.5 | 58.7 | 146.4 | 10.0 | 3.2 | 15.9 | 0 | 0 | 4.98 K | 19.8 K | 2.5 K |
| Cash From Financing Activities | 463.0 | 190.2 | 239.3 | 576.4 | 6.1 | 424.3 | 58.7 | 96.9 | 78.3 | 35.5 | 23.3 | 1.7 | 5.5 | 1.9 | 19.8 K | 0 |
| CHANGE IN CASH | ||||||||||||||||
| Net Change In Cash | (56.8) | 153.8 | 11.5 | 53.4 | (62.7) | (63.2) | 38.7 | 73.1 | (31.3) | 25.2 | 19.7 | (0.5) | (0.8) | 1.3 | 5.35 K | 57.3 K |
| FREE CASH FLOW | ||||||||||||||||
| Free Cash Flow | (384.1) | (313.2) | (265.5) | (251.9) | (165.8) | (102.4) | (79.7) | (34.2) | (19.5) | (10.2) | (3.7) | (2.2) | (6.2) | (0.6) | 14.4 K | 57.3 K |